ARTERIAL CHEMOINFUSION IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREAS CANCER.
P G TarazovA V KozlovD A GranovA V PavlovskiyA A PolikarpovE V RozengausS A PopovE V VlasovaV E MoiseenkoPublished in: Vestnik khirurgii imeni I. I. Grekova (2018)
The chemoinfusions (310) were carried out in celiac trunk
in 167 patients with non-removed pancreas cancer at the period
from 2000 to 2015. Locally advanced timorous process (stage III,
n=79) was revealed in 79 patients and liver metastases (stage IV,
n=88) were noted in 88 cases. The celiac axis infusion by Gemcitabine
(1000 mg/m²) was applied for patients and GEMOX
(Gemcitabine+Oxaliplatin 75 mg/m²) has been using since 2012.
Symptomatic improvement such as decrease of pain, growth
of body weight was noted in majority of patients. An average
lifetime, median and one-year survival consisted of 7,6 months,
5,8 months and 10%. The patients (133) were treated by 1–2
cycles and after that by course of total body chemotherapeutics.
There weren’t any serious complications. Toxic manifestations
of chemotherapy weren’t higher than I–II degree and they were
arrested by corrective therapy in 92 patients (55%). The celiac
axis infusion is safe in patients with locally advanced and inoperable
pancreas cancer. Symptomatic improvement showed the
most patients. The objective response to the treatment had 20%
patients and performance of repeated cycles led to increase of
their survival.